# A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

> **NCT00514917** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 413 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Leuprolide
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT00514917
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 413 (ACTUAL)
- **Why stopped:** Company decision to discontinue the study, not due to any safety or efficacy concerns
- **Last updated:** 2013-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00514917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00514917, "A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00514917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*